G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Rapid Estrogen Signaling and Translational Research

Executive Summary: G-1 (CAS 881639-98-1) is a potent and selective GPR30 agonist with a Ki of ~11 nM, exhibiting minimal affinity for ERα/ERβ at micromolar concentrations (APExBIO). G-1 rapidly activates GPR30-mediated intracellular signaling, including calcium mobilization (EC50 = 2 nM) and PI3K pathway activation, distinct from classical estrogen receptor mechanisms (Wang et al., 2021). Preclinical benchmarks include inhibition of breast cancer cell migration (IC50: 0.7–1.6 nM), reduction of cardiac fibrosis, and improved cardiac contractility in rat heart failure models. G-1 is insoluble in water and ethanol but dissolves at ≥41.2 mg/mL in DMSO, supporting reliable experimental use. APExBIO provides G-1 (B5455) as a validated reagent for translational research in cardiovascular, endocrine, and oncology domains.

Biological Rationale

Estrogen signaling is mediated by classical nuclear receptors (ERα, ERβ) and the G protein-coupled estrogen receptor (GPR30/GPER1). GPR30 is primarily localized on the endoplasmic reticulum membrane and mediates rapid, non-genomic estrogen responses. These rapid effects include modulation of intracellular calcium, PI3K signaling, and cell migration. G-1 is a synthetic, non-steroidal compound that selectively activates GPR30 without significant activity at nuclear ERs, enabling researchers to dissect GPR30-specific pathways (Wang et al., 2021). GPR30 activation has been implicated in immunomodulation following hemorrhagic shock, rapid cardiovascular protection, and inhibition of tumor cell migration (GSK3B.com).

Mechanism of Action of G-1 (CAS 881639-98-1), a selective GPR30 agonist

G-1 binds to GPR30 with high affinity (Ki ~11 nM), triggering receptor-specific intracellular signaling. Upon activation, GPR30 stimulates G protein-coupled cascades, including rapid elevation of cytosolic calcium and PI3K-mediated nuclear accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3). These events are distinct from the transcriptional regulation mediated by ERα or ERβ. In breast cancer cell lines (e.g., SKBr3, MCF7), G-1 inhibits cell migration at sub-nanomolar concentrations (IC50: 0.7 nM, 1.6 nM, respectively). In vivo, G-1 reduces brain natriuretic peptide (BNP), inhibits cardiac fibrosis, and improves contractility in ovariectomized Sprague-Dawley rats with experimental heart failure. These cardioprotective effects involve normalization of β1-adrenergic receptor and upregulation of β2-adrenergic receptor expression (APExBIO).

Evidence & Benchmarks

• G-1 selectively binds GPR30 (Ki ~11 nM), with negligible binding to ERα/ERβ at ≥1 μM concentrations (APExBIO).
• G-1 induces intracellular calcium mobilization in GPR30+ cells (EC50 = 2 nM) (Wang et al., 2021).
• In SKBr3 and MCF7 breast cancer cells, G-1 inhibits migration with IC50 values of 0.7 nM and 1.6 nM, respectively (GSK3B.com).
• Chronic G-1 administration in ovariectomized rat heart failure models reduces BNP, suppresses cardiac fibrosis, and improves contractility (Wang et al., 2021).
• G-1 stock solutions are soluble in DMSO at ≥41.2 mg/mL but insoluble in water/ethanol; recommended storage is at −20°C (APExBIO).

This article expands mechanistic insights beyond prior summaries such as Unraveling GPR30-Selective Estrogen Signaling by focusing on direct evidence from recent in vivo and immunological models, and clarifies the solubility and handling parameters critical for reproducible experiments.

Applications, Limits & Misconceptions

G-1 is utilized in cardiovascular, endocrine, oncology, and immunological research to dissect GPR30-dependent pathways. Its selectivity enables attribution of observed effects to GPR30, excluding confounding ERα/ERβ-mediated mechanisms. G-1 has facilitated understanding of rapid estrogen signaling in immune cell function post-trauma, cardiac remodeling, and metastatic processes.

Common Pitfalls or Misconceptions

• Not a pan-estrogen receptor agonist: G-1 does not activate ERα or ERβ at concentrations up to 1 μM; effects seen in their absence are GPR30-specific (Wang et al., 2021).
• Solubility limitations: G-1 is insoluble in water and ethanol. DMSO is required for stock preparation; improper solubilization reduces assay reliability (APExBIO).
• No long-term DMSO solution storage: G-1 solutions degrade if stored at −20°C for extended periods; fresh aliquots are recommended for each experiment.
• Not effective in ERβ-dominant contexts: G-1 does not substitute for ERβ agonists in models where ERβ drives the phenotype (Wang et al., 2021).
• Dosage precision required: Low nanomolar efficacy mandates accurate dilution and handling to avoid off-target or null results.

For a deeper dive into immune modulation and translational context, see Unlocking GPR30's Role in Immune Modulation, which this article updates by including rigorous preclinical heart failure benchmarks and solubility details.

Workflow Integration & Parameters

• Preparation: Dissolve G-1 in DMSO at concentrations ≥41.2 mg/mL; warming and ultrasonic bath may enhance dissolution (product page).
• Stock storage: Aliquot solutions and store at −20°C; avoid repeated freeze-thaw cycles.
• Working solutions: Dilute freshly in compatible buffers for cell culture or animal dosing. DMSO concentration in final assays should not exceed cell/tissue tolerance.
• Concentration guidance: Use low-nanomolar to sub-micromolar range for in vitro studies; adjust for in vivo models as per published protocols (Wang et al., 2021).
• Controls: Include ERα/ERβ agonists and GPR30 antagonists (e.g., G15) as comparators for specificity validation.

For broader strategic deployment of G-1 in advanced cardiovascular and oncology pipelines, see Selective GPR30 Agonist for Advanced Cardiovascular Studies, which focuses more on pathway integration, while this article provides detailed solubility and workflow parameters.

Conclusion & Outlook

G-1 (CAS 881639-98-1) is a validated, highly selective GPR30 agonist, enabling precise study of rapid estrogen signaling in diverse research applications. Its robust in vitro and in vivo benchmarks make it indispensable for dissecting GPR30-mediated effects in cardiovascular, oncology, and immunological models. As a product of APExBIO, G-1 (B5455) offers reproducible performance for experimental systems requiring strict receptor selectivity. Ongoing advances in non-classical estrogen signaling research will continue to benefit from G-1's specificity and robust experimental track record. For additional specifications, refer to the G-1 (CAS 881639-98-1) product page.